

LIPID PROFILE AND CLINICAL CHARACTERISTICS OF WOMEN WITH GESTATIONAL DIABETES MELLITUS AND PREECLAMPSIA

LIPIDSKI PROFIL I KLINIČKE KARAKTERISTIKE ŽENA SA GESTACIONIM DIJABETES MELITUSOM I PREEKLAMPSIJOM

Donovan McGrowder¹, Kevin Grant¹, Rachael Irving², Lorenzo Gordon³, Tazhmoye Crawford², Ruby Alexander-Lindo², Yeiny Terry Pena Fraser³

¹Department of Pathology, Faculty of Medical Sciences, University of the West Indies, Kingston 7, Jamaica

²Department of Basic Medical Sciences, Faculty of Medical Sciences, University of the West Indies, Kingston 7, Jamaica

³Department of Medicine, Faculty of Medical Sciences, University of the West Indies, Kingston 7, Jamaica

Summary: Gestational diabetes mellitus (GDM) is associated with increased risk of pregnancy-induced hypertension and other maternal and foetal complications of pregnancy. The aims of the study were to evaluate the serum lipid profile of women with GDM, and determine the number of women with GDM who have preeclampsia (PE). A retrospective study of 84 women with GDM and 90 pregnant women with normal glucose tolerance (controls) was conducted. Women with GDM had significantly higher parity ($p=0.047$), total cholesterol ($p=0.039$) and triglycerides ($p=0.033$), but non-significantly lower HDL-cholesterol ($p=0.086$) when compared to controls. Systolic blood pressure was significantly elevated in women with GDM coupled with PE (GDM-PE; $p=0.015$), the mean birth weight of infants born to women with GDM-PE was significantly lower than that of women with only GDM ($p=0.025$). Women with GDM-PE had significantly higher triglycerides ($p=0.020$), had to be more multi-gravida ($p=0.047$) with significantly elevated VLDL-cholesterol ($p=0.037$) when compared with women with only GDM. 11.9% of women with GDM had PE. On the basis of these findings, it can be concluded that GDM is associated with hyperlipidaemia as evident by the significantly elevated total cholesterol and triglyceride concentrations. Women with dyslipidaemia and GDM are at risk of developing preeclampsia. It is imperative that blood lipids be evaluated in women with GDM during antenatal care as it would be helpful in the early detection and treatment of PE.

Keywords: gestational diabetes mellitus, preeclampsia, glucose, lipids, prevalence

Address for correspondence:

Dr. Donovan McGrowder
Department of Pathology, Faculty of Medical Sciences
University of the West Indies, Mona, Kingston 7, Jamaica.
Tel: 1-876-927-1410; Fax: 1-876-977-3942
e-mail: dmcgrowd@yahoo.com

Kratak sadržaj: Gestacioni dijabetes melitus (GDM) povezan je sa povećanim rizikom od hipertenzije izazvane trudnoćom i drugih komplikacija trudnoće kod majke i fetusa. Ciljevi studije bili su da se odredi lipidski profil žena sa GDM, i utvrdi broj žena sa GDM koje imaju PE. Sprovedena je retrospektivna studija 84 žene sa GDM i 90 trudnica sa normalnom tolerancijom glukoze (kontrola). Žene sa GDM imale su značajno povišen paritet ($p=0,047$), ukupni holesterol ($p=0,039$) i trigliceride ($p=0,033$), ali i neznajčno niži HDL-holesterol ($p=0,086$) u poređenju sa kontrolom. Sistolni krvni pritisak bio je značajno povišen kod žena sa GDM u kombinaciji sa PE (GDM-PE; $p=0,015$), a prosečna težina novorođenčadi koju su rodile žene sa GDM-PE bila je značajno niža nego kod žena sa GDM ($p=0,025$). Žene sa GDM-PE imale su značajno povišene trigliceride ($p=0,020$), i sklonije su većem broju trudnoća ($p=0,047$) uz značajno povišen VLDL-holesterol ($p=0,037$), u poređenju sa ženama samo sa GDM. 11,9% žena sa GDM imalo je PE. Na osnovu tih nalaza može se zaključiti da je GDM povezan sa hiperlipidemijom, što se vidi iz značajno povišenih ukupnih koncentracija holesterola i triglicerida. Kod žena sa dislipidemijom i GDM postoji rizik od razvoja preeklampsije. Veoma je važno određivati lipide u krvi žena sa GDM u okviru prenatalne zaštite jer to pomaže ranom otkrivanju i lečenju PE.

Ključne reči: gestacioni dijabetes melitus, preeklampsija, glukoza, lipidi, prevalenca

Introduction

Pregnancy is commonly recognized as a state of physiological and temporary insulin resistance. This condition is driven by high concentrations of steroid hormones such as progesterone, estrogens, prolactin, cortisol and placenta-derived human placental lactogen. All of these are diabetogenic and combined cause decreased sensitivity of insulin receptors within target tissues (1). Gestational diabetes mellitus (GDM) is defined as carbohydrate intolerance of varying degrees of severity with onset or first recognition during pregnancy (2).

Gestational diabetes mellitus is the most common medical and metabolic complication of pregnancy, occurring in 1–14% of patients depending on the population described and the criteria used for diagnosis (3). It is a heterogeneous disorder in which age, obesity, and genetic background contribute to the severity of the disease. Women with GDM are at risk for later development of type 2 diabetes. Coustan and colleagues studied women who had previous gestational diabetes and found diabetes or impaired glucose tolerance (IGT) in 6% of those tested at 0–2 years, 13% for those tested at 3–4 years, 15% at 5–6 years, and 30% at 7–10 years postpartum (4). Other studies have documented type 2 diabetes at 3–5 years postpartum in 30–50% of women who had a pregnancy complicated by GDM (5, 6).

Gestational diabetes mellitus is accompanied by alterations in fasting, postprandial, and integrated 24h plasma concentrations of amino acids, glucose, and lipids. These changes include a 3-fold increase in plasma triglyceride concentration during the third trimester of pregnancy, elevation of plasma fatty acids, delayed postprandial clearance of fatty acids, and elevation of branched-chain amino acids (7). Clark and colleagues reported that women with GDM have higher triglycerides, free fatty acids and beta-hydroxybutyrate and lower high density lipoprotein (HDL) cholesterol than normal pregnant subjects (8). Therefore, women with prior GDM are at greater risk for developing hypertension, hyperlipidaemia and electrocardiogram abnormalities (9).

Maternal morbidity due to GDM may be immediate or long-term. Studies documented an increase in preeclampsia (PE), polyhydramnios, and operative delivery in pregnancies complicated by GDM (10, 11). The Toronto Tri-Hospital Gestational Diabetes Project, a prospective cohort study evaluating maternal and foetal outcomes with increasing carbohydrate intolerance, observed a significant association between glucose intolerance and an increased incidence of caesarean delivery, PE, and length of maternal hospitalization (11).

The abnormalities of carbohydrate metabolism observed in GDM may lead to other abnormalities such as those observed in insulin resistance, espe-

cially lipid abnormalities. Women with pregestational and GDM have been reported to have increased risk of PE (10–50 and 10–30%, respectively) and insulin resistance when compared with women with normal glucose tolerance whose rate of preeclampsia is 5–7% (12–15). Dyslipidaemia may contribute to PE as changes in plasma lipids may induce endothelial disturbances (16). This study therefore investigated the lipidaemic status, and the number of women with GDM who have PE.

Subjects and Methods

Subjects

An observational retrospective study in pregnant patients admitted to maternity wards of the University Hospital of the West Indies was conducted between January 2005 and December 2006. The test population consisted of 84 women with GDM and 94 women with normal glucose tolerance (controls) in the third trimester of pregnancy. Subjects were matched by gestational age. This study was approved by the University of the West Indies Ethics Committee. Inclusion criteria for enrollment included GDM according to the diagnostic criteria of the Third International Conference on Gestational Diabetes (2); gestational age between 28 and 34 weeks as determined by a clinical examination before 12 weeks and/or an ultrasound before 20 weeks; entry fasting serum glucose concentration of 7.2 mmol/L and no history of hypertension, renal, or other chronic medical disease; and negative antipancreatic islet cell antibodies. The patients were instructed to continue their usual diets and physical activities.

Gestational diabetes mellitus is usually detected in the second trimester; however since the prevalence of diabetes in Jamaica is high and can pre-date the pregnancy (17), it was important to screen for diabetes early in the first trimester. Fasting plasma glucose is used to eliminate women being classified as GDM whose diabetes might likely antedate their pregnancy (18). All women in the study were screened at nine weeks of gestation for glucose intolerance using the 50 g glucose O'Sullivan Test (5). Women with plasma glucose concentrations ≥ 7.8 mmol/L subsequently underwent 75 g of oral glucose tolerance test (OGTT), with threshold plasma glucose concentrations of 5.3, 10.2, and 8.6 mmol/L for fasting, 1 hour and 2 hour respectively (19). The O'Sullivan Test was repeated at 24–28 weeks of gestation on participants with normal O'Sullivan test results or OGTT results. The diagnosis of GDM was based on the World Health Organization's OGTT criteria (19) because the revised criteria do not affect the prevalence of GDM (20). The O'Sullivan test was repeated at 32 weeks of gestation on participants with normal O'Sullivan or OGTT results.

Blood pressure

Blood pressure was taken by qualified obstetric nurses using a mercury sphygmomanometer and stethoscope. Measurements were taken from the left upper arm after subjects had been sitting for >5 min in accordance with the recommendation of the American Heart Association (21). Triplicate measurements were taken with a 5 min rest interval between measurements and the mean value was recorded.

Hypertension in pregnancy is defined as the presence of a blood pressure of 140/90 mmHg taken twice 6 hours apart or a rise of 30 mmHg in systolic pressure or 15 mmHg in diastolic pressure (22). The first and fifth Korotkoff auscultatory sounds were used to determine the systolic and diastolic components. Preeclampsia is defined as hypertension associated with excretion of more than 300 mg of urinary protein per 24 hours or a rise in serum uric acid level of more than 1 mg per deciliter, a decrease in the platelet count of more than 50,000 per cubic millimeter, or both (23, 24). The classification followed the guidelines of the American College of Gynaecology and Obstetrics (25).

Biochemical analysis

Biochemical assays on the serum were performed with a multichannel autoanalyzer (c8000, Abbott Diagnostics, USA). Parameters that were determined include: total cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), very low density lipoprotein cholesterol (VLDL-C). Serum LDL-C was calculated by Frederickson-Friedewald's formula according to which $LDL-C = TC - (HDL-C + VLDL-C)$. Calculation of VLDL-C was 1/5 of triglyceride concentration. Total cholesterol was determined by an enzymatic method (26), and triglyceride by an analytical methodology based on the sequence of

reaction described by Fossati and colleagues (27). The atherogenic index (AI) was calculated as $[(TC - HDL-C)/HDL-C]$ (28). The methods adopted by the automated instrument for the determination of the above parameters are according to the manufacturer's instruction—Abbott Laboratories (Abbott Diagnostics, Illinois, USA).

Serial venous blood samples were collected and assayed for serum levels of urea and electrolytes, albumin, calcium, magnesium, phosphorous, uric acid, urea and creatinine utilizing a multi-channel autoanalyzer (c8000, Abbott Diagnostics, USA).

Statistical analysis

Values for the continuous variables are expressed as mean \pm SEM. Comparisons of women with GDM against the control group were performed using unpaired students t tests, a level of $p < 0.05$ was considered as statistically significant. Data was analyzed by the Student's t-test for independent samples and the Fisher test for independent test with the level of significance set at 5%. Statistical significance was also assessed by the Mann-Whitney U test (29). Statistics were computed using SPSS 11.5 (SPSS Inc., Chicago, Illinois, United States).

Results

The two study groups were of similar maternal and gestational age, systolic and diastolic blood pressures (SBP and DBP, *Table I*). Women with GDM had significantly higher parity ($p=0.047$); but difference in gravida, birth weight of infant, haemoglobin concentrations were not significantly different from healthy pregnant controls ($p>0.05$). As expected, women with GDM had higher mean fasting, 1h, and 2h blood glucose concentrations compared with controls ($p=0.001$; *Table II*); mean HbA1c concen-

Table I Clinical characteristics of women with GDM and controls.

| Biochemical parameters | GDM | Control | p value |
|-------------------------|-------------------|-------------------|---------|
| Maternal age (yrs) | 30.18 \pm 0.88 | 29.61 \pm 1.03 | 0.474 |
| Gestational age (weeks) | 38.29 \pm 0.28 | 38.23 \pm 0.79 | 0.946 |
| SBP (mmHg) | 116.54 \pm 1.82 | 115.23 \pm 2.29 | 0.651 |
| DBP (mmHg) | 72.81 \pm 1.28 | 71.59 \pm 1.91 | 0.582 |
| Gravida (number) | 2.86 \pm 0.07 | 1.96 \pm 0.20 | 0.063 |
| Parity (number) | 1.10 \pm 0.16 | 0.62 \pm 0.15* | 0.047 |
| Birth weight (kg) | 3.09 \pm 0.08 | 3.15 \pm 0.09 | 0.655 |
| Haemoglobin (g/L) | 11.36 \pm 0.17 | 11.09 \pm 0.21 | 0.316 |

Data are presented as Mean \pm S.E.

* $P < 0.05$ GDM group compared with controls.

Table II Biochemical parameters of women with GDM and control.

| Biochemical parameters | GDM | Control | p value |
|---------------------------|----------------|----------------|---------|
| Sodium (mmol/L) | 134.66 ± 0.34 | 135.86 ± 0.27 | 0.080 |
| Potassium (mmol/L) | 3.83 ± 0.07 | 3.77 ± 0.07 | 0.409 |
| Chloride (mmol/L) | 107.13 ± 0.47 | 108.17 ± 1.29 | 0.550 |
| Urea (mmol/L) | 2.68 ± 0.15 | 3.25 ± 0.92 | 0.389 |
| Bicarbonate (mmol/L) | 17.00 ± 0.42 | 17.01 ± 1.74 | 0.644 |
| Creatinine (μmol/L) | 65.15 ± 3.33 | 63.84 ± 1.74 | 0.702 |
| Total protein (g/L) | 65.87 ± 1.93 | 66.31 ± 1.25 | 0.847 |
| Albumin (g/L) | 35.26 ± 0.83 | 33.62 ± 0.55 | 0.950 |
| Globulins (g/L) | 30.33 ± 1.46 | 32.35 ± 1.01 | 0.263 |
| Uric acid (mmol/L) | 0.39 ± 0.04 | 0.31 ± 0.02 | 0.146 |
| Total bilirubin (μmol/L) | 5.23 ± 0.47 | 6.42 ± 0.92 | 0.069 |
| Direct bilirubin (μmol/L) | 2.16 ± 0.21 | 2.48 ± 0.31 | 0.001 |
| ALP (U/L) | 111.62 ± 11.32 | 116.77 ± 12.76 | 0.137 |
| GGTP (U/L) | 28.62 ± 4.50 | 19.23 ± 2.19 | 0.656 |
| AST (U/L) | 21.29 ± 2.23 | 27.46 ± 3.54 | 0.873 |
| CPK (U/L) | 80.95 ± 10.19 | 113.95 ± 12.67 | 0.110 |
| LDH (U/L) | 203.76 ± 14.40 | 183.35 ± 14.14 | 0.895 |
| HBA1c (%) | 5.90 ± 0.34 | 4.60 ± 0.67 | 0.001 |
| Glucose (F) (mmol/L) | 5.50 ± 0.20** | 4.60 ± 0.38 | 0.001 |
| Glucose (1 h) (mmol/L) | 9.69 ± 0.43** | 4.80 ± 0.33 | 0.001 |
| Glucose (2 h) (mmol/L) | 8.54 ± 0.42** | 4.03 ± 0.38 | 0.001 |
| Calcium (mmol/L) | 2.17 ± 0.03 | 2.15 ± 0.03 | 0.239 |
| Phosphorous (mmol/L) | 1.24 ± 0.06 | 1.18 ± 0.06 | 0.581 |
| Magnesium (mmol/L) | 0.79 ± 0.02 | 0.82 ± 0.02 | 0.200 |

Data are presented as Mean ± S.E.

**P < 0.01 GDM group compared with controls.

Table III Blood lipids of women with GDM and controls.

| Lipid parameters | GDM | Control | p value |
|----------------------------|--------------|-------------|---------|
| Total cholesterol (mmol/L) | 5.71 ± 0.24* | 5.01 ± 0.32 | 0.039 |
| Triglyceride (mmol/L) | 1.83 ± 0.10* | 1.43 ± 0.20 | 0.033 |
| HDL-cholesterol (mmol/L) | 1.25 ± 0.08 | 1.45 ± 0.08 | 0.086 |
| VLDL-cholesterol (mmol/L) | 0.34 ± 0.02 | 0.33 ± 0.05 | 0.799 |
| LDL-cholesterol (mmol/L) | 3.32 ± 0.24 | 3.05 ± 0.34 | 0.727 |
| Atherogenic index | 3.19 ± 0.24 | 3.14 ± 0.35 | 0.904 |
| LDL-C : HDL-C ratio | 2.71 ± 0.23 | 2.67 ± 0.29 | 0.926 |
| TC : HDL-C ratio | 3.35 ± 0.23 | 3.23 ± 0.11 | 0.990 |
| TG : HDL-C ratio | 1.24 ± 0.08 | 1.21 ± 0.20 | 0.900 |
| HDL-C : VLDL-C ratio | 3.75 ± 0.40 | 3.95 ± 0.25 | 0.571 |

Data are presented as Mean ± S.E.

*P < 0.05 GDM group compared with controls.

Table IV Clinical characteristics of women with GDM and GDM-PE.

| Biochemical parameters | GDM | GDM-PE | p value |
|-------------------------|---------------|----------------|---------|
| Maternal age (yrs) | 30.32 ± 0.96 | 28.83 ± 2.83 | 0.530 |
| Gestational age (weeks) | 38.30 ± 0.27 | 38.00 ± 1.32 | 0.733 |
| SBP (mmHg) | 115.44 ± 1.73 | 130.00 ± 2.66* | 0.015 |
| DBP (mmHg) | 71.98 ± 1.33 | 78.83 ± 2.83 | 0.073 |
| Gravida (number) | 2.50 ± 0.21 | 4.00 ± 0.33* | 0.047 |
| Parity (number) | 1.09 ± 0.18 | 1.20 ± 0.37 | 0.882 |
| Birth weight (kg) | 3.12 ± 0.08 | 2.58 ± 0.54* | 0.025 |
| Proteinuria (g/day) | 0.09 ± 0.01 | 1.02 ± 0.11** | 0.001 |
| Haemoglobin (g/L) | 11.41 ± 0.17 | 11.10 ± 0.70 | 0.316 |

Data are presented as Mean ± S.E.

*P < 0.05 GDM-PE group compared with GDM group; **P < 0.01 GDM-PE group compared with GDM group.

Table V Biochemical parameters of women with GDM and GDM-PE.

| Biochemical parameters | GDM | GDM-PE | p value |
|---------------------------|----------------|----------------|---------|
| Sodium (mmol/L) | 134.63 ± 0.38 | 134.83 ± 0.75 | 0.841 |
| Potassium (mmol/L) | 3.78 ± 0.07 | 4.20 ± 0.13* | 0.032 |
| Chloride (mmol/L) | 107.18 ± 0.53 | 106.83 ± 0.95 | 0.797 |
| Urea (mmol/L) | 2.69 ± 0.17 | 2.63 ± 0.18 | 0.902 |
| Bicarbonate (mmol/L) | 17.02 ± 0.47 | 16.83 ± 0.54 | 0.881 |
| Creatinine (μmol/L) | 65.67 ± 3.37 | 72.17 ± 7.90 | 0.481 |
| Total protein (g/L) | 65.96 ± 2.29 | 66.31 ± 1.25 | 0.104 |
| Albumin (g/L) | 35.54 ± 0.97 | 33.62 ± 0.55 | 0.449 |
| Globulins (g/L) | 30.12 ± 1.64 | 32.35 ± 1.01 | 0.750 |
| Uric acid (mmol/L) | 0.37 ± 0.04 | 0.28 ± 0.03 | 0.327 |
| Total bilirubin (μmol/L) | 5.23 ± 0.47 | 6.42 ± 0.92 | 0.275 |
| Direct bilirubin (μmol/L) | 2.25 ± 0.31 | 2.48 ± 0.31 | 0.564 |
| ALP (U/L) | 103.38 ± 13.67 | 141.80 ± 15.41 | 0.231 |
| LDH (U/L) | 223.38 ± 17.70 | 196.00 ± 11.37 | 0.611 |
| Calcium (mmol/L) | 2.10 ± 0.03 | 2.29 ± 0.06** | 0.003 |
| Phosphorous (mmol/L) | 1.13 ± 0.06 | 1.30 ± 0.08 | 0.162 |
| Magnesium (mmol/L) | 0.60 ± 0.05 | 0.85 ± 0.02 | 0.208 |

Data are presented as Mean ± S.E.

*P < 0.05 GDM-PE group compared with GDM group; **P < 0.01 GDM-PE group compared with GDM group.

tration was also significantly higher in women with GDM ($p=0.001$).

From the lipid profile, women with GDM had significantly higher total cholesterol ($p=0.039$) and triglyceride concentrations ($p=0.033$), but non-significantly lower HDL-cholesterol ($p=0.086$) compared with controls (*Table III*). LDL-cholesterol, atherogenic

index, and TC:HDL-cholesterol ratio were higher in women with GDM-PE compared with women with only GDM; however, these differences did not attain significance.

Gestational age, maternal age, parity and haemoglobin concentration were similar in women with GDM and those with GDM-PE (*Table IV*). Systolic

Table VI Blood lipids of women with GDM and GDM-PE.

| Lipid parameters | GDM | GDM-PE | p value |
|----------------------------|-------------|--------------|---------|
| Total cholesterol (mmol/L) | 5.08 ± 0.32 | 6.00 ± 0.62 | 0.185 |
| Triglycerides (mmol/L) | 1.47 ± 0.10 | 2.13 ± 0.21* | 0.020 |
| HDL-cholesterol (mmol/L) | 1.59 ± 0.10 | 1.35 ± 0.07 | 0.194 |
| VLDL-cholesterol (mmol/L) | 0.32 ± 0.02 | 0.43 ± 0.04* | 0.037 |
| LDL-cholesterol (mmol/L) | 3.09 ± 0.26 | 3.43 ± 0.70 | 0.572 |
| Atherogenic index | 3.09 ± 0.28 | 3.62 ± 0.52 | 0.291 |
| LDL-C : HDL-C ratio | 2.55 ± 0.26 | 2.99 ± 0.31 | 0.476 |
| TC : HDL-C ratio | 3.51 ± 0.28 | 3.82 ± 0.52 | 0.580 |
| TG : HDL-C ratio | 1.08 ± 0.10 | 1.40 ± 0.23 | 0.262 |
| HDL-C : VLDL-C ratio | 3.96 ± 0.25 | 3.75 ± 0.40 | 0.485 |

Data are presented as Mean ± S.E.

*P < 0.05 GDM-PE group compared with GDM group

blood pressure ($p=0.015$) and protein in the urine ($p=0.001$) were significantly elevated in women with GDM-PE, and the mean birth weight of infants born to women with GDM-PE was significantly lower than that of women with only GDM ($p=0.025$). Women with GDM-PE had significantly higher gravida ($p=0.047$); however, even though DBP was higher in women with GDM-PE, it did not attain significance (Table IV). Women with GDM-PE had significantly lower mean potassium ($p=0.032$) and calcium ($p=0.003$) concentrations compared with controls, although these values fall within the normal reference ranges (Table V). Alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) activities were higher in women with GDM-PE compared with women with only GDM; however, the differences were not significant.

Triglyceride ($p=0.020$) and VLDL-cholesterol concentrations ($p=0.037$) were significantly elevated in patients with GDM-PE when compared to women with only GDM (Table VI). Women with GDM-PE had higher total cholesterol, LDL-cholesterol, atherogenic index and LDL-cholesterol:HDL-cholesterol ratio, total cholesterol:HDL-cholesterol ratio; however, these were not significantly different from women with only GDM ($p>0.05$).

Discussion

This study revealed that women with GDM have significantly elevated serum total cholesterol and triglyceride concentrations compared to pregnant

women with normal glucose tolerance. Women with GDM also have higher LDL-cholesterol and atherogenic index but lower HDL-cholesterol. However, these differences were not statistically significant. Ten of the eighty four (11.9%) women with GDM had preeclampsia. Systolic blood pressure was significantly elevated in women with GDM-PE, and the mean birth weight of infants born to women with GDM-PE was significantly lower than that of women with only GDM. Women with GDM-PE had significantly lower serum potassium and calcium concentrations compared to women with only GDM, although these values fall within the normal reference ranges.

High serum oestrogen concentrations and increasing insulin resistance in late pregnancy are considered to be responsible for the hypertriglyceridaemia observed during normal pregnancy. Cholesterol is used by the placenta for steroid synthesis and fatty acids are used for placental oxidation and membrane formation (30). Changes in total cholesterol concentration reflect changes in the various lipoprotein fractions. Total and LDL-cholesterol concentrations decreased initially, but then increased in the second and third trimesters. HDL-cholesterol increased by the 12th week of gestation in response to oestrogen and remains elevated throughout pregnancy (30). VLDL-cholesterol and triglycerides decreased in the first 8 week of gestation and then continuously increased until full term. In the second half of pregnancy, VLDL-cholesterol clearance is altered because of the decreased activity of lipoprotein lipase (LPL) in the adipose and liver and because of the increased activity in the placenta (30).

The abnormalities of carbohydrate metabolism observed in GDM may lead to other abnormalities (most commonly the typical abnormalities seen in insulin resistance), especially lipid abnormalities. Metabolic studies carried out demonstrated that women with GDM have multiple defects in insulin action together with impaired compensation for insulin resistance. These defects in the regulation of glucose production, glucose clearance and free fatty acid concentrations, along with defects in pancreatic β -cell function, precede the development of type 2 diabetes in women with GDM. Insulin resistance and type 2 diabetes mellitus are associated with a clustering of interrelated plasma lipid and lipoprotein abnormalities, which include elevated triglyceride concentrations, decreased HDL-cholesterol and a predominance of LDL-cholesterol particles (31). This dyslipidaemic profile has also been noted in pregnancies complicated by GDM in various case control studies (32–34). However, not all results from these studies are in consonance with each other. The dyslipidaemia profile observed in our study is not in accordance with reports from some other investigations. Knopp and colleagues studied 22 women with GDM and 38 controls in the third trimester of pregnancy (35). These authors found increased plasma concentrations of triglycerides and VLDL-cholesterol but no difference in plasma cholesterol concentrations in women with GDM (35). Montelongo and colleagues in their study also reported no differences in total cholesterol and triglyceride between women with GDM and controls in their first, second or third trimester (36). In addition, Bartha and colleagues reported that maternal total cholesterol and triglyceride concentrations were similar in GDM and normal pregnancy (33). In our study, the LDL-cholesterol concentration in women with GDM was higher than in controls but there was no significant difference. The discrepancies among studies may be the result of false negative tests of the null hypothesis in studies with smaller sample sizes, as well as other methodological differences (37).

In this study, the triglyceride concentration was significantly elevated in women with GDM with higher LDL-cholesterol and VLDL, although these were not statistically significantly different from the controls. The hypertriglyceridaemia seen in controls and those with GDM who had a family history of early onset autosomal dominant type 2 diabetes may be due to defective lipolysis of very LDL-triglyceride (38, 39). A large number of mutations in lipoprotein lipase (LPL) have been identified and these can cause hypertriglyceridaemia (40). However, it is doubtful that most cases of endogenous hypertriglyceridaemia can be explained by mutations in LPL, which appear to be relatively rare. Decreased LDL catabolism may account for the rise in plasma LDL-cholesterol concentration (36).

Gestational diabetes mellitus is relatively common and affects 3–5 percent of pregnancies, resulting in a variety of complications that primarily affect the foetus, including macrosomia, stillbirth, jaundice,

and respiratory distress syndrome (41). Like GDM, hypertensive disorders of pregnancy complicate 5–10 percent of all pregnancies and can result in a variety of maternal and foetal complications, including seizures, stroke, hepatic failure, renal failure, intrauterine growth retardation, foetal distress, premature delivery, and death (42). The pathophysiology of pregnancy-induced hypertension (PIH) is poorly understood, but it is likely multifactorial; several lines of evidence suggest that glucose intolerance and insulin resistance have a role in the etiology of these diseases (43).

The findings of this study revealed that 11.9% of women with GDM had PE (GDM-PE). This value falls within the range of 10–30% reported by a number of investigators (12–15). Women with GDM-PE had significantly elevated triglycerides and VLDL-cholesterol compared to women with only GDM. In addition, women with GDM-PE had higher total cholesterol, atherogenic index, LDL-cholesterol:HDL-cholesterol ratio, total cholesterol:HDL-cholesterol ratio and triglyceride:HDL-cholesterol ratio, but these were not significantly different from women with only GDM. Women with GDM-PE had infants with significantly lower birth weights compared with women with only GDM. A possible explanation of this finding is that preeclampsia of early onset (≤ 37 weeks) may be more likely to be severe, have a detrimental effect on fetal growth, and lead to iatrogenic premature delivery. Preeclampsia that is of late onset (> 37 weeks) may be more likely to be mild and less likely to lead to iatrogenic premature delivery (44).

The elevated triglyceride concentrations in women with GDM-PE could be explained by overproduction of VLDL in the liver due to hyperlipidaemia and resistance of lipoprotein lipase to insulin action which is a characteristic feature of the insulin-resistance syndrome (45). The VLDL-cholesterol concentration as reported by some researchers might increase up to 2.5 folds at term over the pre-pregnancy concentrations (46, 47). The VLDL-cholesterol increased even further in preeclampsia perhaps due to increased VLDL lipoproteins, which accumulate over the maternal vascular endothelium particularly those of the uterine and renal vessels (48). Further VLDL-cholesterol may cause injury to the endothelium, while a specific toxicity-preventing-activity-protein (the pl 5.6 form of plasma albumin) protects against VLDL-induced injury in the pathogenic process of toxemia (49).

The relation between PIH and GDM is not well understood. While there are several studies that have suggested an association between these diseases (50–52), there are those which have not found any association (53, 54). One cohort study of 10,666 women in Sweden examined risk factors for gestational hypertension and PE (55). This study reported a significantly 3.16-fold increased risk of PE among

mothers with gestational diabetes compared with mothers without gestational diabetes, but it was unable to demonstrate a statistically significant 1.34-fold increased risk of gestational hypertension (55). A prospective study of women participating in a calcium supplementation trial for the prevention of PE also demonstrated that the degree of abnormal glucose tolerance was associated with PE (56). This study also suggested that women with gestational diabetes have a 1.67-fold increased risk of developing PE (56). A French study of 15 maternity units also found an association between gestational diabetes and a significantly 2.86-fold increased risk of developing PIH among women with gestational diabetes (57).

This study was carried out in a black population. Interactions such as ethnicity and the development of PIH were not investigated in this study. A study by Bryson and colleagues found interactions between ethnicity and gestational diabetes regarding their association with eclampsia and severe preeclampsia.

The risk of PIH associated with gestational diabetes was highest among mothers of black ethnicity, followed by Hispanic and Caucasian. They also suggested that both ethnicity and prenatal care modified the association between gestational diabetes and PIH (58).

It was found that GDM is associated with hyperlipidaemia as evidenced by the significantly elevated total cholesterol and triglyceride concentrations. Dyslipidaemia in women with gestational diabetes increases their risk of developing PE. These findings should greatly contribute to the understanding of the aforementioned disorders. It is imperative that blood lipids be evaluated in women with GDM during antenatal care since it would be helpful in the early detection and treatment of PE.

References

- Desoye G, Schweditsch MO, Pfeiffer KP, Zechner R, Kostner GM. Correlation of hormones with lipid and lipoprotein levels during normal pregnancy and postpartum. *J Clin Endocrinol Metab* 1987; 64: 704–12.
- Metzger BE. Organizing Committee: Summary and recommendations of the Third International Workshop-Conference on Gestational Diabetes Mellitus. *Diabetes* 1991; 40: 197–201.
- Coustan DR. Gestational diabetes. In: *Diabetes in America*, 2nd Edition. Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH, Eds. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 1995; 703–17.
- Coustan DR, Carpenter MW, O'Sullivan PS, Carr SR. Gestational diabetes: predictors of subsequent disordered glucose metabolism. *Am J Obstet Gynecol* 1993; 168: 1139–45.
- O'Sullivan JB, Mahan CM. Criteria for the glucose tolerance test in pregnancy. *Diabetes* 1964; 13: 278–85.
- Mestman JH, Anderson GV, Guadalupe V. Follow-up studies of 360 subjects with abnormal carbohydrate metabolism during pregnancy. *Obstet Gynecol* 1972; 39: 421–5.
- Metzger BE, Phelps RL, Freinkel N, Navickas IA. Effects of gestational diabetes on diurnal profiles of plasma glucose, lipids and individual amino acids. *Diabetes Care* 1980; 3: 402–9.
- Clark MC, Qiu C, Amerman B, et al. Gestational diabetes: should it be added to the syndrome of insulin resistance? *Diabetes Care* 1997; 20 (5): 867–71.
- O'Sullivan JB. Long term follow-up of gestational diabetes. In: *Early Diabetes*. Camerinidavalos, RA, Cole HS (eds), Academic Press, New York, 1984; 1009–27.
- De Veciana M, Major CA, Morgan MA, Asrat T, Toohey JS, Lien JM, et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. *N Engl J Med* 1995; 333 (19): 1237–41.
- Sermer M, Naylor CD, Gare DJ, et al. Impact of increasing carbohydrate intolerance on maternal fetal outcomes in 3637 without gestational diabetes: the Toronto Tri Hospital Gestational Diabetes Project. *Am J Obstet Gynecol* 1995; 173: 146–56.
- Innes KE, Wimsatt JH. Pregnancy-induced hypertension and insulin resistance: evidence for a connection. *Acta Obstet Gynecol Scand* 1999; 78: 263–84.
- Kaaja R, Tikkanen MJ, Viinikka L, Ylikorkala O. Serum lipoproteins, insulin, and urinary prostanoid metabolites in normal and hypertensive pregnant women. *Obstet Gynecol* 1995; 85: 353–6.
- Martinez Abundis E, Gonzalez Ortiz M, Quinones Galvan A, Ferrannini E. Hyperinsulinemia in glucose-tolerant women with preeclampsia: a controlled study. *Am J Hypertens* 1996; 9: 610–14.
- Lorentzen B, Birkeland K, Endresen M, Henriksen T. Glucose intolerance in women with preeclampsia. *Acta Obstet Gynecol Scand* 1998; 77: 22–7.
- Lorentzen B, Henriksen T. Plasma lipids and vascular dysfunction in preeclampsia. *Sem Reprod Endocrinol* 1998; 16: 33–9.
- Ragoobirsingh D, Lewis-Fuller E, Morrison E. The diabetes survey. A protocol for the Caribbean. *Diabetes Care* 1995; 18 (9): 1277–9.
- Sacks D, Chen W, Wolde-Tsadiq G, Buchanon T. Fasting plasma glucose test at first prenatal visit as a screen for gestational diabetes. *Obstetrics & Gynaecology* 2003; 101: 1197–203.

19. World Health Organization. Diabetes mellitus, report of a WHO Study Group. Geneva: WHO Tech Rep Ser 727, 1985.
20. Ko G, Tam WH, Chen JC, Rogers M. Prevalence of gestational diabetes mellitus in Hong Kong based on 1998 criteria. *Diabetic Medicine* 2002; 19: 80.
21. Kirkendall WM, Burton AC, Epstein FH, Freis ED. Recommendations for human blood pressure determination by sphygmomanometers. *Circulation* 1967; 36: 980–8.
22. Hughes EC, ed. Obstetric-gynecological terminology. Philadelphia: FA Davis, 1972.
23. Gifford RW, August P, Chesley LC, et al. National high blood pressure education program working group report on high blood pressure in pregnancy. *Am J Obstet Gynecol* 1990; 163: 1691–712.
24. Chesley LC. Diagnosis of preeclampsia. *Obstet Gynecol* 1985; 65: 423–5.
25. National High Blood Pressure Education Program: Working group report in pregnancy. US Department of Health and Human Services, 1991; 1–38.
26. Flegg HM. An investigation of the determination of serum cholesterol by an enzymatic method. *Ann Clin Biochem* 1973; 10: 79–84.
27. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. *Clinical Chemistry* 1982; 28: 2077–80.
28. Schonfield G. Lipoproteins in atherogenesis. *Artery* 1979; 5: 305–29.
29. Feinstein A. Clinical epidemiology, the architecture of clinical research. 1st ed. WB Saunders Co, 1985.
30. Meyers-Seifer CH, Vohr BR. Lipid levels in former gestational diabetic mothers. *Diabetes Care* 1996; 19: 1351–6.
31. Krauss R. Lipids and lipoproteins in patients with type 2 diabetes. *Diabetes Care* 2004; 27: 1496–504.
32. Couch SC, Philipson EH, Bendel RB, Wijendran V, Lammi-Keefe CJ. Maternal and cord plasma lipid and lipoprotein concentrations in women with and without gestational diabetes mellitus. Predictors of birth weight? *J Reprod Med* 1998; 43 (9): 816–22.
33. Bartha JL, Comino-Delgado R, Martinez-Del-Fresno P, Fernandez-Barríos M, Bethencourt I, Moreno-Corral L. Insulin-sensitivity index and carbohydrate and lipid metabolism in gestational diabetes. *J Reprod Med* 2000; 45 (3): 185–9.
34. Bower J, Hadi H, Barakat HA. Plasma lipoprotein subpopulation distribution in Caucasian and African-American women with gestational diabetes. *Diabetes Care* 2001; 24: 169–71.
35. Knopp RH, Chapman M, Bergelin R, Wahl PW, Warth MR, Irvine S. Relationships of lipoprotein lipids to mild fasting hyperglycemia and diabetes in pregnancy. *Diabetes Care* 1980; 3: 416–20.
36. Montelongo A, Lasuncion MA, Pallardo LF, Herrera E. Longitudinal study of plasma lipoproteins and hormones during pregnancy in normal and diabetic women. *Diabetes* 1992; 41: 1651–9.
37. Koukkou E, Watts GF, Lowy C. Serum lipid, lipoprotein and apolipoprotein changes in gestational diabetes mellitus: a cross-sectional and prospective study. *J Clin Pathol* 1996; 49: 634–7.
38. Boberg J, Carlson LA, Freyschuss U, Lassers BW, Wahlqvist ML. Splanchnic secretion rates of plasma triglycerides and total and splanchnic turn-over of plasma free fatty acids in men with normo- and hypertriglyceridaemia. *Eur J Clin Invest* 1992; 9: 454–66.
39. Dunn FL, Grundy SM, Bilheimer DW, Havel RJ, Raskin P. Impaired catabolism of very low-density lipoprotein-triglyceride in a family with primary hypertriglyceridaemia. *Metabolism* 1985; 34: 316–24.
40. Lalouel JM, Wilson DE, Iverius P. Lipoprotein lipase and hepatic triglyceride lipase. *Molecular and Genetic Aspects. Curr Opin Lipidol* 1992; 3: 86–95.
41. Suhonen L, Teramo K. Hypertension and pre-eclampsia in women with gestational glucose intolerance. *Acta Obstet Gynecol Scand* 1993; 72: 269–72.
42. Walker JJ. Pre-eclampsia. *Lancet* 2000; 356: 1260–5.
43. Solomon CG, Seely EW. Brief review: hypertension in pregnancy: a manifestation of the insulin resistance syndrome? *Hypertension* 2001; 37: 232–9.
44. Xiong X, Demianczuk NN, Buekens P, et al. Association of preeclampsia with high birth weight for gestational age. *Am J Obstet Gynecol* 2000; 183: 148–55.
45. Knudsen P, Eriksson J, Lahdenpera S, Kahri J, Groop L, Taskinen MR, the Botnia Study Group. Changes of lipolytic enzymes cluster with insulin resistance syndrome. *Diabetologia* 1995; 38: 48–53.
46. Teichmann AT, Wieland H, Cremer P, Knlow G, Mehle U. Serum lipid and lipoprotein concentrations in pregnancy and at onset of labour in normal and complicated pregnancies caused by hypertensive gestosis and fetal growth retardation. *Geburtshilfe Frauenheilkd (Germany, West)* 1988; 48 (3): 134–9.
47. Knopp RH, Warth MR, Charles D, Childs M, Li JR, Mabuchi H, Von MIA. Lipoprotein metabolism in pregnancy, fat transport to the fetus and the effects of diabetes. *Biol Neonate (Switzerland)* 1986; 50 (6): 297–317.
48. Potter JM, Netel PJ. The hyperlipidaemia of pregnancy in normal and complicated pregnancies. *Am J Obstet Gynaecol* 1979; 133 (2): 165–70.
49. Arbogast BW, Leeper SC, Merrick RD, Olive KE, Taylor RN. Which plasma factors bring about disturbance of endothelial function in preeclampsia? *Lancet* 1994; 343 (8893): 340–1.
50. Jensen DM, Sorensen B, Feilberg-Jorgensen N, et al. Maternal and perinatal outcomes in 143 Danish women with gestational diabetes mellitus and 143 controls with a similar risk profile. *Diabet Med* 2000; 17: 281–6.
51. Conde-Agudelo A, Belizan JM. Risk factors for pre-eclampsia in a large cohort of Latin American and Caribbean women. *BJOG* 2000; 107: 75–83.
52. Nordlander E, Hanson U, Persson B. Factors influencing neonatal morbidity in gestational diabetic pregnancy. *Br J Obstet Gynecol* 1989; 96: 671–8.

53. Cousins L. Pregnancy complications among diabetic women: review 1965–1985. *Obstet Gynecol Surv* 1987; 42:140–9.
54. Jacobson JD, Cousins L. A population-based study of maternal and perinatal outcome in patients with gestational diabetes. *Am J Obstet Gynecol* 1989; 161: 981–6.
55. Ros HS, Cnattingius S, Lipworth L. Comparison of risk factors for preeclampsia and gestational hypertension in a population based cohort study. *Am J Epidemiol* 1998; 147: 1062–70.
56. Joffe GM, Esterlitz JR, Levine RJ, et al. The relationship between abnormal glucose tolerance and hypertensive disorders of pregnancy in healthy nulliparous women. Calcium for Preeclampsia Prevention (CPEP) Study Group. *Am J Obstet Gynecol* 1998; 179: 1032–7.
57. Vambergue A, Nuttens MC, Goeusse P, et al. Pregnancy induced hypertension in women with gestational carbohydrate intolerance: the digest study. *Eur J Obstet Gynecol Reprod Biol* 2002; 102: 31–5.
58. Bryson CL, Loannou N, Rulyak SJ, Critchlow C. Association between Gestational Diabetes and Pregnancy-induced Hypertension. *Am J Epidemiol* 2003; 158: 1148–53.

Received: January 29, 2009

Accepted: April 3, 2009